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Kaposi's sarcoma (KS) is a highly vascular tumour, which was ﬁrst described by the Hungarian derma-
tologist Moritz Kaposi Kohn before the discovery of the human immunodeﬁciency virus (HIV). Histori-
cally, KS has been linked to immunosuppression or to elderly male patients, especially in relation to
diffuse cutaneous KS. We describe a case of Bronchopulmonary Kaposi's sarcoma in a patient with AIDS
who was successfully treated with HAART and Liposomal Doxorubicin chemotherapy.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Kaposi's sarcoma (KS) is a highly vascular tumour, which was
ﬁrst described by the Hungarian dermatologist Moritz Kaposi Kohn
before the discovery of the human immunodeﬁciency virus (HIV). It
is caused by a herpes virus e human herpes virus 8 (HHV-8) e and
is considered as one of the most common acquired immunodeﬁ-
ciency syndrome (AIDS) deﬁning illnesses. Bronchopulmonary KS is
not an uncommon presentation in patients with AIDS, especially in
relation to diffuse cutaneous KS [1].
Case presentation
A 48-year-old Polish man was initially diagnosed with AIDS and
skin Kaposi's sarcoma, during a visit to his home country. He pre-
sented to our department one year after the diagnosis, following
the onset of new symptoms including shortness of breath on
exertion, dry cough, and a mildly raised temperature. He looked
unwell on admission to the hospital; his observations indicated
tachycardia and no particular respiratory signs. The rest of the ex-
amination was unremarkable, apart from multiple skin lesions
observed on his face, upper trunk, and legs. His medical back-
ground included mild asthma.
Laboratory tests showed the following: Haemoglobin 14.3 g/dl,
leukocytes 5.1 x 109/l, CRP 1 mg/l, HIV-1RNA 1050 copy/ml, lym-
phocytes Ab's 1.33 x 109/l, CD4 T helper cells 2%, CD4 T helper cells
0.02 x 109/l, CD8 T suppressor cells 54%, CD8 T suppressor cells 0.71
x109/l. The Ziehl Neelsen stain for acid-fast bacilli was negative.
The chest radiograph on admission displayed clear lung ﬁelds. A
CT scan was subsequently performed, which revealed patchyN. Bashar), Nicholas.innes@
chhopsital.nhs.uk (J. Orrell).
Ltd. This is an open access article uground glass attenuation in all lobes, consistent with atypical
infection. Based on these results, the patient was started on a high
dose of intravenous antibiotics, to which he initially responded
well, but failed to recover completely. Due to the persistence of his
symptoms, a ﬁbreoptic bronchoscopy was performed, along with
biopsies which were sent for histopathology. During the bron-
choscopy, a violaceous lesion was seen at the level of the right
upper lobe take-off (Fig 1a). The histopathology indicated poorly
formed vascular structures, which were highlighted in the immu-
nohistochemistry for CD31, CD34, and Factor 8 (Fig. 2). This
conﬁrmed the suspicion of Kaposi's sarcoma.
The patient was started on HAART and Liposomal Doxorubicin
chemotherapy, which led to a marked improvement of his skin
lesions and the resolution of the endobronchial Kaposi's (Fig. 1b). It
was also noted that his CD4 count and the viral loadwere stabilised.
He was then covered for opportunistic fungal infection with anti-
biotic prophylaxis.
One year after the chemotherapy, the patient visited the chest
clinic with symptoms of shortness of breath occasionally associated
with reduced exercise distance, no sputum, and no haemoptysis.
Spirometry showed an obstructive picture with reversibility post
bronchodilator, which was in keeping with his diagnosis of asthma.
A CT scan revealed the ﬁndings of bilateral consolidation/atelec-
tasis, which could represent resolving infection. Fibreoptic bron-
choscopy revealed no signs of KS; however, one of his sputum
samples grewMycobacterium Kansasii, for which hewas started on
a treatment of antibiotics for eighteen months.Discussion
Kaposi's sarcoma is a tumour involving blood vessels and lym-
phatics. It is one of the highly vascular tumours and hence has a
high risk of bleeding. KS is associated with the herpes virus (KSHV)nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Appearances of Bronchopulmonary KS pre. (1a) and post (1b) treatment.
Fig. 2. Histopathology appearances of Bronchopulmonary KS.
N. Bashar et al. / Respiratory Medicine Case Reports 15 (2015) 45e4746and this has been considered as the causative factor for KS, with a
mechanism involving the reactivation of the latent virus in
immunocompromised patients [2]. Historically, KS has been linked
to immunosuppression or to elderly male patients; however, there
are reported cases which suggest its occurrence in immunocom-
petent young patients as well.
There are four main subtypes of KS with different clinical pre-
sentations: epidemic or AIDS related; endemic or African; classic or
sporadic; and immunocompromised. The KS form which is related
to AIDS has mostly been linked to homosexual men. There are
fewer reported cases among women and heterosexuals [3].
Although a few cases have been reported as isolated visceral
manifestations of KS, it is very uncommon for visceral involvement
to occur without skin manifestations [4,5]. Visceral disease may
affect the gastrointestinal tract, lungs, liver, and spleen. Pulmonary
KS can present a wide range of symptoms and signs: progressive
dyspnoea, dry cough, and low grade fever are the most frequent
presentations [6]. Imaging, particularly CT, plays an important role
in the diagnosis of KS lesions within the lungs. However, in order to
conﬁrm pulmonary involvement, it is crucial to perform a bron-
choscopy [4,7].
There are many factors to be considered before deciding on how
to treat KS. The National Cancer Institute recommends four
different modalities of treatment that can be used in conjunction
with the HIV treatment: radiation therapy, surgery, chemotherapy,
and biological therapy. Since the introduction of highly active an-
tiretroviral therapy (HAART) there has been a signiﬁcant reduction
in the rates of AIDS deﬁning illnesses in general, including KS [8,9].A study conducted by Gbabe et al. looked into the outcomes of
treating patients with HAART alone, as against the usual usage of
HAART and chemotherapy together [10]. They concluded that using
HAART and chemotherapy together is superior to using HAART
alone, especially with regard to progressive diseases. However, the
results have not identiﬁed any difference between various
chemotherapy regimens. Liposomal doxorubicin is widely used as
the ﬁrst line of chemotherapy, since it has been proved to be more
effective when compared to other agents [11].
In conclusion, KS is one of the frequent complications of AIDS. In
most cases, Bronchopulmonary KS occurs in patients who have had
cutaneous involvement. In the author's experience of several cases,
endobronchial biopsy has not caused signiﬁcant haemorrhaging
and has, in fact, helped in the conﬁrmation of the diagnosis.
Combining HAART and chemotherapy is the current standard
treatment for Kaposi's sarcoma.References
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